US Patent

US8334279 — Non-hormonal steroid modulators of NF-κB for treatment of disease

Method of Use · Assigned to Validus Genetics · Expires 2029-05-28 · 3y remaining

Vulnerability score 76/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compounds and methods for treating or preventing muscular dystrophy and other muscular wasting diseases.

USPTO Abstract

The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, including muscular dystrophy.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3747 — Agamree

Patent Metadata

Patent number
US8334279
Jurisdiction
US
Classification
Method of Use
Expires
2029-05-28
Drug substance claim
No
Drug product claim
No
Assignee
Validus Genetics
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.